Data highlights the WATCHMAN FLX device provided statistically superior protection from bleeding, demonstrated similar efficacy compared to blood thinners in patients with non-valvular atrial fibrilla ...
Physicians wrestled with endpoint composition, low event rates, a possible difference in ischemic strokes, and more.
Boston Scientific (NYSE:BSX) announced new findings from the CHAMPION-AF trial supporting its Watchman FLX system.
CHAMPION-AF finds left atrial appendage closure and anticoagulation therapy for atrial fibrillation about equal but raises doubts about whether the former is a true alternative.
Boston Scientific (NYSE:BSX) executives highlighted new data from two randomized clinical trials during an American College of Cardiology conference call, describing the results as potentially ...
A device smaller than a quarter is giving heart patients a new lease on life. The Watchman device is implanted in the heart to prevent blood clots from forming without the need of blood thinners. This ...
The noninferiority trial of patients at risk for both bleeding and stroke, in a surprise turn, found standard care to be ...
The Cottage Heart & Vascular Center’s structural heart team at Santa Barbara Cottage Hospital (SBCH) recently performed their 1,000th WATCHMAN device procedure, a minimally invasive solution for ...
MedStar Heart & Vascular Institute now offers patients with irregular heart rhythm a minimally invasive option to reduce the risk of stroke, as well as enable stopping long-term use of blood thinning ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results